Home Cart Sign in  
Chemical Structure| 1957203-01-8 Chemical Structure| 1957203-01-8

Structure of YKL-5-124
CAS No.: 1957203-01-8

Chemical Structure| 1957203-01-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

YKL-5-124 is a highly selective, covalent CDK7 inhibitor with IC50 value of 9.7nM. It causes arrest at the G1/S transition and inhibition of E2F-driven gene expression, but resulted in no change to Pol II CTD phosphorylation.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of YKL-5-124

CAS No. :1957203-01-8
Formula : C28H33N7O3
M.W : 515.61
SMILES Code : O=C(N(C1)C(C)(C)C2=C1C(NC(C3=CC=C(NC(C=C)=O)C=C3)=O)=NN2)N[C@@H](C4=CC=CC=C4)CN(C)C
MDL No. :MFCD34469131
InChI Key :KPABJHHKKJIDGX-JOCHJYFZSA-N
Pubchem ID :121443990

Safety of YKL-5-124

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of YKL-5-124

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Hela cells 62.5 nM 6 h To validate the inhibitory effect of YKL-5-124 on CDK7 in cells, results showed that YKL-5-124 effectively inhibited CDK7 activity at low concentrations, while YKL-5-167 showed no significant inhibition. PMC6588464
RPP631 cells 100 nM 6 h Confirm the selective targeting of YKL-5-124 to CDK7 by Western blotting analysis of Cyclin H and Cyclin K pull down results. PMC7277075
DMS79 cells 100 nM 24 h Analyze the phosphorylation status of RNA Pol II, CDK1, CDK2, etc., by Western blotting to confirm the inhibitory effect of YKL-5-124 on CDK1 and CDK2. PMC7277075
MDA-MB-231 2500 nM 48 h Evaluate the effect of CDK7 inhibitors on cell cycle and transcription, results show that YKL-5-124 does not directly impact transcription PMC10300262
AMO1 cells 50 nM 24 h To evaluate the impact of YKL-5-124 alone or in combination with JQ1 on the transcriptome of AMO1 cells, results showed that combination therapy had a more profound impact on the transcriptome than single-agent therapy. PMC11694116
JLat10.6 cells 100 nM 20 h YKL-5-124 inhibited HIV-1 induction at non-toxic concentrations PMC10923280
JLat9.2 cells 100 nM 20 h YKL-5-124 also showed inhibitory effects on HIV-1 expression in JLat9.2 cells PMC10923280
MDA-MB-468 1 μM 48 h To evaluate the synergistic effects of YKL-5-124 combined with abemaciclib, results showed that the combination treatment significantly suppressed TNBC cell proliferation and clonogenicity. PMC11791979
Hs578T 0.5 μM 48 h To evaluate the synergistic effects of YKL-5-124 combined with abemaciclib, results showed that the combination treatment significantly suppressed TNBC cell proliferation and clonogenicity. PMC11791979
HAP1 cells 125 nM to 2 μM 24 hours Inhibition of CDK1 and CDK2 T-loop phosphorylation PMC6588464

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice RPP orthotopic model Intraperitoneal injection 10 mg/kg Once daily, five times a week for 3 weeks Evaluate the inhibitory effect of YKL-5-124 on SCLC tumor growth, results showed that YKL-5-124 significantly delayed tumor growth and prolonged the survival of mice. PMC7277075
SCID mice Multiple myeloma xenograft model Intraperitoneal injection 2.5 mg/kg 5 days/week for 2 weeks To evaluate the therapeutic efficacy of YKL-5-124 alone or in combination with JQ1 in a multiple myeloma xenograft model, results showed that combination therapy significantly inhibited tumor growth. PMC11694116
Mice MDA-MB-468 and MDA-MB-231 xenograft models Intraperitoneal injection 2 mg/kg and 5 mg/kg Once daily for 2 weeks (MDA-MB-231) or 3 weeks (MDA-MB-468) To validate the in vivo synergistic effects of YKL-5-124 combined with abemaciclib, results showed that the combination treatment significantly reduced tumor weight and induced apoptosis. PMC11791979

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.94mL

0.39mL

0.19mL

9.70mL

1.94mL

0.97mL

19.39mL

3.88mL

1.94mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories